Syros Pharmaceuticals (SYRS) Will Make Late-Breaking Presentation of SY-1425 Data at SABCS

November 21, 2016 8:05 AM EST
Get Alerts SYRS Hot Sheet
Trade SYRS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Syros Pharmaceuticals (Nasdaq: SYRS) announced that new data on its lead candidate, SY-1425, a selective retinoic acid receptor alpha (RARα) agonist, will be highlighted in a late-breaking presentation at the San Antonio Breast Cancer Symposium (SABCS) taking place December 6-10, 2016, in San Antonio.

The presentation will feature new preclinical data showing that SY-1425 represents a potentially promising therapeutic approach for defined subsets of breast cancer patients whose tumors are driven by abnormally high expression of the RARA gene.

Details on the presentations are as follow:

Date & Time: Saturday, December 10, from 7:30 - 9:00 am CSTPresentation Title: A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor α agonist treatmentSession: Treatment: Novel Targets and Targeted AgentsPresenter: Michael R. McKeown, Ph.D., Senior Scientist, Syros PharmaceuticalsProgram Number: P6-11-18Location: Henry B. Gonzalez Convention Center, Hall 1

SY-1425 is currently in a Phase 2 clinical trial in genomically defined subsets of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Using its gene control platform, Syros discovered subsets of AML, MDS and breast cancer patients whose tumors have a highly specialized regulatory region of non-coding DNA, known as a super-enhancer, associated with the RARA gene, which codes for the RARα transcription factor. The super-enhancer is believed to lead to over-expression of the RARA gene, locking cells in an immature, undifferentiated and proliferative state. Treatment with SY-1425 in cancer cells with this super-enhancer promotes differentiation of these cells.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment